Pharmacol Rev
Currently, the FDA relies on manufacturers to report supply levels, which raises concerns about transparency and whether financial incentives might influence these reports

Combining with other weight loss agents Tesofensine + GLP-1 agonists (theoretical): Different mechanisms = potential synergy Tesofensine: Metabolic + CNS appetite GLP-1s : Strong appetite + gastric slowing Could enhance weight loss to 20-25%+ BUT: No clinical data, significant risks Not recommended without supervision Potential combination benefits: Address multiple pathways Overcome plateaus Better than either alone (theoretically) Metabolic boost + strong appetite suppression Maximum fat loss Combination risks: Compounded cardiovascular strain Unknown drug interactions Excessive weight loss risks Cost ($1,500-2,000/month) Safer alternatives to tesofensine combinations: Tirzepatide alone (15-22% loss, FDA approved) CagriSema (sema + cagrilintide, 15-25%) GLP-1 + lifestyle (safer, proven) Learn about peptide stacking strategies at SeekPeptides
In Phase 2 substudies, Retatrutide cleared an astonishing amount of excess liver fat
Notably for the marketing community, Ro bypassed external creative agencies for this high-stakes placement
I am hiking trails I never would have attempted before